Bleeding with anticoagulant treatments

Hamostaseologie

Volumn 31, Issue 4, 2011, Pages 237-242

  Palareti, G ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Anticoagulation; Bleeding; New oral anticoagulants; Vitamin K anta gonists

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 9; CLOPIDOGREL; CYTOCHROME P450 2C9; DABIGATRAN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; RIVAROXABAN; TINZAPARIN; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE DISEASE; AGE; ANEMIA; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL (TOPIC); COMORBIDITY; DRUG MONITORING; DRUG SAFETY; GENE MUTATION; GENETIC POLYMORPHISM; HEART ATRIUM FIBRILLATION; HEREDITY; HIGH RISK PATIENT; HUMAN; LUNG EMBOLISM; MEDICAL HISTORY; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK FACTOR; STROKE; THROMBOSIS; TREATMENT DURATION; TREATMENT INDICATION; UPPER GASTROINTESTINAL BLEEDING; VENOUS THROMBOEMBOLISM;

AGE DISTRIBUTION; ANTICOAGULANTS; COMORBIDITY; DRUG TOXICITY; HEMORRHAGE; HUMANS; PREVALENCE; RISK ASSESSMENT; RISK MANAGEMENT; SEX DISTRIBUTION; SURVIVAL ANALYSIS; SURVIVAL RATE; THROMBOEMBOLISM; VITAMIN K;

EID: 83755206976     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/ha-1151     Document Type: Review

References (61)

1. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694.
2. Levi M, Hovingh GK, Cannegieter SC et al. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008; 111: 4471-4476.
3. Fanikos J, GrassoCorrenti N, Shah R et al. Major bleeding complications in a specialized anticoagulation service. Am J Cardiol 2005; 96: 595-598.
4. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a metaanalysis. Ann Intern Med 2003; 139: 893-900.
5. Vecsler M, Loebstein R, Almog S et al. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 2006; 95: 205-211.
6. Joffe HV, Xu R, Johnson FB et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 2004; 91: 1123-1128.
7. Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293.
8. Meckley LM, Wittkowsky AK, Rieder MJ et al. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 2008; 100: 229-239.
9. Aithal GP, Day CP, Kesteven PJL et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-719.
10. Schwarz UI, Ritchie MD, Bradford Y et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999-1008.
11. Sconce EA, Khan TI, Wynne HA et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-2333.
12. Oldenburg J, Quenzel EM, Harbrecht U et al. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 1997; 98: 240-244.
13. Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-428.
14. Fihn SD, Callahan CM, Martin DC et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996; 124: 970-979.
15. Steffensen FH, Kristensen K, Ejlersen E et al. Major haemorrhagic complications during oral anticoagulant therapy in a danish population-based cohort. J Intern Med 1997; 242: 497-503.
16. Wickramasinghe LSP, Basu SK, Bansal SK. Longterm oral anticoagulant therapy in elderly patients. Age Ageing 1988; 17: 388-396.
17. Redwood M, Taylor C, Bain BJ et al. The association of age with dosage requirement for warfarin. Age Ageing 1991; 20: 217-220.
18. Keeling D. Duration of anticoagulation: decision making based on absolute risk. Blood Rev 2006; 20: 173-178.
19. Hylek EM, Singer DE. Risk factors far intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
20. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage -facts and hypotheses. Stroke 1995; 26: 1471-1477.
21. Palareti G, Hirsh J, Legnani C et al. Oral anticoagulation treatment in the elderly -A nested, prospective, case-control study. Arch Intern Med 2000; 160: 470-478.
22. Fang MC, Chang YC, Hylek EM et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141: 745-752.
23. Shorr RI, Ray WA, Daugherty JR et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153: 1665-1670.
24. Longstreth GF. Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage: a population-based study. Am J Gastro enterol 1997; 92: 419-424.
25. Smith EE, Rosand J, Knudsen KA et al. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology 2002; 59: 193-197.
26. Torn M, Algra A, Rosendaal FR. Oral anticoagulation for cerebral ischemia of arterial origin: high initial bleeding risk. Neurology 2001; 57: 1993-1999.
27. Dahl T, Abildgaard U, Sandset PM. Long-term anticoagulant therapy in cerebrovascular disease: does bleeding outweigh the benefit? J Intern Med 1995; 237: 323-329.
28. Petty GW, Brown RD, Whisnant JP et al. Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention -A population-based study. Ann Intern Med 1999; 130: 14-22.
29. Algra A. Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage. Stroke 2003; 34: E45-E6.
30. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-99.
31. Kuijer PMM, Hutten BA, Prins MH et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159: 457-460.
32. Palareti G, Legnani C, Lee A et al. A comparison of the safety and efficacy of oral antiocoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000; 84: 805-810.
33. Hutten BA, Prins MH, Gent M et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis. J Clin Oncol 2000; 18: 3078-3083.
34. Prandoni P, Lensing AWA, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
35. Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: A meta-analysis and hypothesis. Cerebrovasc Dis 1999; 9: 215-217.
36. Rothberg MB, Celestin C, Fiore LD et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: Meta-analysis with estimates of risk and benefit. Ann Intern Med 2005; 143: 241-250.
37. Sorensen R, Hansen ML, Abildstrom SZ et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374: 1967-1974.
38. Mellemkjaer L, Blot WJ, Sorensen HT et al. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br J Clin Pharmacol 2002; 53: 173-181.
39. Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med 1989; 87: 153-159.
40. Schulman S, Beyth RJ, Kearon C et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest 2008; 133: 257S-298S.
41. Hylek EM, Go AS, Chang YC et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
42. Hylek EM, EvansMolina C, Shea C et al. Major Hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696.
43. Ansell J, Hirsh J, Hylek E et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest 2008; 133: 160S-198S.
44. Fihn SD, Gadisseur AA, Pasterkamp E et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost 2003; 90: 260-266.
45. Palareti G, Legnani C, Guazzaloca G et al. Risks factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol 2005; 129: 72-78.
46. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158: 1641-1647.
47. Heneghan C, AlonsoCoello P, Garcia Alamino JM et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006; 367: 404-411.
48. Poller L, Keown M, Ibrahim S et al. An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost 2008; 6: 935-943.
49. Lee AYY, Levine MN, Baker RI et al. Low-molecularweight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
50. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
51. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
52. Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
53. Mismetti P, Quenet S, Levine M et al. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism -An individual patient data meta-analysis. Chest 2005; 128: 2203-2210.
54. Petersen JL, Mahaffey KW, Hasselblad V et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes -A systematic overview. JAMA Journal of the American Medical Association 2004; 292: 89-96.
55. FRISC. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354: 708-715.
56. Simonneau G, Sors H, Charbonnier B et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-669.
57. Buller HR, Cohen AT, Davidson B et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094-1104.
58. Buller HR, Cohen AT, Davidson B et al. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007; 357: 1105-1112.
59. Joyner CD, Peters RJ, Afzal R et al. Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. Am Heart J 2009; 157: 502-508.
60. Steffel J, Braunwald E. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thromboembolism. Eur Heart J 2011; doi:10.1093/eurheartj/ehr052.
61. Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817.